论文部分内容阅读
目的:为探讨血清CA153水平与乳腺癌分期和预后的关系。方法:采用ELISA法对74例乳腺癌患者手术前后血清CA153进行检测,同期检测了26例乳腺良性疾病患者及40例正常人血清CA153水平。结果:乳腺癌患者血清CA153明显高于乳腺良性疾病组和正常对照组,其术后20天血清CA153水平明显低于术前;乳腺癌患者血清CA153水平与临床分期密切相关,Ⅲ期患者明显高于Ⅰ、Ⅱ期,且术后20天仍保持在较高水平上。结论:血清CA153的表达水平与乳腺癌患者的临床分期和预后密切相关,可作为鉴别乳腺良、恶性疾病的一项参考指标。
Objective: To investigate the relationship between serum CA153 level and breast cancer staging and prognosis. Methods: Serum CA153 levels in 74 patients with breast cancer before and after operation were measured by ELISA. Serum levels of CA153 in 26 patients with benign breast disease and 40 normal controls were detected at the same period. Results: Serum CA153 in patients with breast cancer was significantly higher than that in benign breast disease group and normal control group. The level of serum CA153 in patients with breast cancer was significantly lower than that before operation. The serum CA153 level in breast cancer patients was closely related to clinical stage, In Ⅰ, Ⅱ period, and 20 days after surgery remained at a high level. Conclusion: The expression level of serum CA153 is closely related to the clinical stage and prognosis of patients with breast cancer, and can be used as a reference index to identify benign and malignant breast diseases.